

TECHNICAL BULLETIN

☒ NEW TEST ☒ TEST CHANGE

NOTIFICATION DATE: 10/30/2023

EFFECTIVE DATE: 10/31/2023

**Prometheus Anser ADA (ANSERADA)
PROMETHEUS Anser IFX (ANSERIFX)**

On the effective date, the Prometheus Anser ADA and PROMETHEUS Anser IFX tests will now be performed by Labcorp (LCA) using their proprietary DoseASSURE™ System. These tests will no longer be performed by Prometheus Laboratories.

The reference intervals for the tests will be updated.

Test Requirement/ Parameters	New	Previous	New	Previous
	Adalimumab & Adalimumab Ab	Prometheus Anser ADA	Infliximab Concentration & Ab	Prometheus Anser IFX
Submission Container/ Tube	Gold Top Tube		Gold Top Tube	
Specimen Volume/ Minimum Volume	2 mL serum (1 mL min)		2 ml serum (1 mL min)	
Reference Interval	Adalimumab drug level		Infliximab drug level	
	<0.6 µg/mL	See Report	<0.4 µg/mL	<1.0 µg/mL
	Antiadalimumab antibody		Anti-infliximab antibody	
	<25 ng/mL	See Report	<22 ng/mL	<1.6 U/mL
Computer Interface Code	ADALIMUMAB	ANSERADA	INFLIXIMAB	ANSERIFX
Test Order	PDM #5903888	PDM #1759070	PDM #5963016	PDM #1759071

If you have any questions, please contact Client Services at (800) 472-5757.